New York State Common Retirement Fund Buys 103,931 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

New York State Common Retirement Fund increased its position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 111.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 197,132 shares of the medical equipment provider's stock after buying an additional 103,931 shares during the period. New York State Common Retirement Fund owned 0.28% of Lantheus worth $17,635,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of LNTH. Kestra Investment Management LLC bought a new position in Lantheus during the fourth quarter valued at $27,000. Centerpoint Advisors LLC bought a new stake in Lantheus during the fourth quarter worth about $224,000. GAM Holding AG bought a new position in shares of Lantheus during the 4th quarter valued at $588,000. Venturi Wealth Management LLC boosted its position in Lantheus by 60.0% during the 4th quarter. Venturi Wealth Management LLC now owns 3,625 shares of the medical equipment provider's stock valued at $324,000 after buying an additional 1,359 shares during the period. Finally, Sanctuary Advisors LLC increased its stake in shares of Lantheus by 58.5% during the fourth quarter. Sanctuary Advisors LLC now owns 18,042 shares of the medical equipment provider's stock valued at $1,674,000 after buying an additional 6,656 shares during the period. Institutional investors own 99.06% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on LNTH shares. JMP Securities reiterated a "market outperform" rating and set a $112.00 price objective on shares of Lantheus in a research note on Tuesday, January 14th. The Goldman Sachs Group initiated coverage on shares of Lantheus in a research note on Wednesday, December 18th. They set a "buy" rating and a $143.00 target price on the stock. StockNews.com downgraded Lantheus from a "buy" rating to a "hold" rating in a research report on Thursday, November 21st. Finally, Truist Financial restated a "buy" rating and issued a $120.00 price target (down from $135.00) on shares of Lantheus in a research report on Friday, November 8th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $131.86.

Remove Ads

Lantheus Price Performance

Shares of LNTH traded up $14.71 during midday trading on Wednesday, reaching $94.76. The stock had a trading volume of 1,568,687 shares, compared to its average volume of 849,357. The company's fifty day simple moving average is $89.77 and its two-hundred day simple moving average is $96.81. Lantheus Holdings, Inc. has a 1-year low of $56.44 and a 1-year high of $126.89. The company has a market cap of $6.59 billion, a price-to-earnings ratio of 15.77 and a beta of 0.44.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The medical equipment provider reported $1.34 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. On average, sell-side analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Insider Buying and Selling at Lantheus

In related news, Director James H. Thrall sold 1,000 shares of the firm's stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the transaction, the director now directly owns 33,207 shares in the company, valued at $3,146,695.32. This trade represents a 2.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.50% of the stock is currently owned by corporate insiders.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.